Literature DB >> 26552747

Comprehensive therapeutic approach for patients with heart failure and comorbidity.

F J Ruiz-Laiglesia1, V Garcés-Horna2, F Formiga3.   

Abstract

The prevalence of heart failure increases with age and is accompanied by other diseases, which are encompassed within a «cardiometabolic phenotype». Their interrelation changes the evolution and treatment that each disease would have in isolation. Patients with heart failure and comorbidity are frail and complex. They require a comprehensive assessment (not just biomedical), which includes functional, cognitive, affective and psychosocial aspects. The overall treatment, which is not covered in the clinical practice guidelines, should adapt to each and every one of the comorbidities. Polypharmacy should be avoided as much as possible, due to its interactions and reduced adherence. Treatment needs to be optimised and adapted to the evolutionary phase of the disease and the specific needs of each patient. The complexity of the care process for patients with heart failure and comorbidities requires the coordination of healthcare providers and support from family and others involved in the patient's care.
Copyright © 2015 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.

Entities:  

Keywords:  Comorbidity; Comorbilidad; Heart failure; Insuficiencia cardíaca; Tratamiento; Treatment

Year:  2015        PMID: 26552747     DOI: 10.1016/j.rce.2015.09.009

Source DB:  PubMed          Journal:  Rev Clin Esp (Barc)        ISSN: 2254-8874


  2 in total

1.  Prognostic influence of prior chronic obstructive pulmonary disease in patients admitted for the first time because of acute heart failure: reply.

Authors:  Francesc Formiga; Karine Luz Londoño; David Chivite
Journal:  Intern Emerg Med       Date:  2018-05-09       Impact factor: 3.397

2.  Prognostic influence of prior chronic obstructive pulmonary disease in patients admitted for their first episode of acute heart failure.

Authors:  Karine Luz Londoño; Francesc Formiga; David Chivite; Rafael Moreno-Gonzalez; Margherita Migone De Amicis; Xavier Corbella
Journal:  Intern Emerg Med       Date:  2018-03-06       Impact factor: 3.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.